Surface Oncology to Participate in H.C. Wainwright Bioconnect 2021 Conference

Rhea-AI Summary

Surface Oncology (Nasdaq: SURF) announced that CEO Jeff Goater will speak at the H.C. Wainwright Bioconnect 2021 Conference from January 11–14, 2021. The presentation will cover key immunotherapy programs, including SRF617 targeting CD39 and SRF388 targeting IL-27, along with a new preclinical program, SRF114 targeting CCR8. Conference attendees can access the discussion on demand starting January 11 at 6:00 a.m. ET. Surface Oncology is focused on developing innovative therapies aimed at the tumor microenvironment to improve anti-tumor responses.

CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Jeff Goater, chief executive officer, will participate in the upcoming H.C. Wainwright Bioconnect 2021 Conference, which will take place January 11–14.

The discussion will focus on Surface Oncology's lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27), as well as Surface’s emerging pre-clinical program, SRF114 (targeting CCR8). The discussion will be available on demand to conference attendees for the duration of the event beginning at 6:00 a.m. ET on Monday, January 11.

About Surface Oncology:

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.

Contacts:

Investors
Matt Lane
matt@gilmartinir.com
617-901-7698

Media
Matthew Corcoran
mcorcoran@tenbridgecommunications.com
617-866-7350

FAQ

What will Jeff Goater discuss at the H.C. Wainwright Bioconnect 2021 Conference?

Jeff Goater will discuss Surface Oncology's lead immunotherapy programs, SRF617 and SRF388, and the preclinical program SRF114.

When is the H.C. Wainwright Bioconnect 2021 Conference?

The conference will take place from January 11 to January 14, 2021.

How can I access Jeff Goater's presentation at the conference?

The discussion will be available on demand to conference attendees starting January 11 at 6:00 a.m. ET.

What is Surface Oncology's focus in developing immunotherapies?

Surface Oncology focuses on developing therapies that target the tumor microenvironment for sustained anti-tumor responses.

What are the key programs mentioned in the press release for Surface Oncology?

The key programs include SRF617 targeting CD39, SRF388 targeting IL-27, and the preclinical SRF114 targeting CCR8.